Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer (AADLPC)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02175212 |
Recruitment Status :
Completed
First Posted : June 26, 2014
Results First Posted : November 4, 2016
Last Update Posted : November 20, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Adenocarcinoma | Drug: Short term androgen deprivation Drug: Long term androgen deprivation Radiation: Short term androgen deprivation Radiation: Long term androgen deprivation | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 362 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer. |
Study Start Date : | November 2005 |
Actual Primary Completion Date : | June 2014 |
Actual Study Completion Date : | September 24, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Long term androgen deprivation
|
Drug: Long term androgen deprivation
Other Name: Neoadjuvant, concomitant and adjuvant Radiation: Long term androgen deprivation Minimum dose of 76 Gy (range 76-82 Gy) |
Active Comparator: Short term androgen deprivation
|
Drug: Short term androgen deprivation
Other Name: Neoadjuvant and concomitant Radiation: Short term androgen deprivation Minimum dose of 76 Gy (range 76-82 Gy) |
- Biochemical Disease Free Survival: Estimated Percentage of Participants With Biochemical Disease-free Survival at 5 Years [ Time Frame: 5 years ]Biochemical relapse was defined as the time from inclusion in the study (randomization) until the patient meets criteria for Biochemical failure (Phoenix criteria: PSA nadir plus 2 ng/ml).
- Metastasis Free Survival: Estimated Percentage of Participants With Metastasis-free Survival at 5 Years [ Time Frame: 5 years ]Metastasis free survival: defined as the time from inclusion in the study (randomization) until the appearance of distant metastases: a positive result in any of the tests performed (scintigraphy, chest radiography, thorax, abdominal and pelvic CT and MRI).
- Overall Survival: Estimated Percentage of Participants Alive at 5 Years [ Time Frame: 5 years ]Overall Survival: defined as the time that elapses from the patient enters the study until the patient dies from any cause.
- Cause-specific Survival [ Time Frame: 5 years ]Cause-specific survival included all deaths from prostate cancer or treatment complications, and deaths from unknown causes in patients with either active cancer or a previously documented relapse
- Late Toxicity [ Time Frame: 5 years ]
Defined as the maximal rectal, urinary and cardiovascular (CV) toxicity per patient more than 90 days after completion of RT.
Scoring scales used were the radiation morbidity scoring criteria of the European Organization for Research and Treatment of Cancer-Radiation Therapy Oncology Group (EORTC/RTOG) and the Common Terminology Criteria for Adverse Events (CTCAEs) v 3.0 for the remained toxicity.
CV events were defined according to the World Health Organization criteria
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histological proven adenocarcinoma of the prostate
- Stage: cT1c-3b N0M0 according to American Joint Committee on Cancer (AJCC) Tumor Node Metastasis (TNM)
- Prostatic Specific Antigen (PSA)<100 ng/ml
- Intermediate (T1-T2 with Gleason Score [GS] 7 and/or PSA 10-20)
- High risk (T3 and/or GS 8-10 and/or PSA > 20)
- Karnofsky Index (KI) performance status ≥70%
- Written informed consent
Exclusion Criteria:
- T4 N1 M1,
- Previous surgical treatment (prostatectomy or cryosurgery)
- Neoadjuvant hormonal treatment > 3 months.
- History of pelvic radiotherapy (RT)
- Contraindications for radiotherapy
- Concomitant use of chemotherapy
- Serious psychiatric or medical condition
- Current synchronic malignancies
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02175212
Spain | |
Hospital Universitario de la Princesa | |
Madrid, Spain, 28006 |
Principal Investigator: | Almudena Zapatero, MD PhD, IP | Grupo de Investigación Clínica en Oncología Radioterapia |
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa |
ClinicalTrials.gov Identifier: | NCT02175212 |
Other Study ID Numbers: |
DART01/05 |
First Posted: | June 26, 2014 Key Record Dates |
Results First Posted: | November 4, 2016 |
Last Update Posted: | November 20, 2020 |
Last Verified: | November 2020 |
Patients with prostate adenocarcinoma |
Adenocarcinoma Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Ascorbic Acid Methyltestosterone Androgens Estrogens, Conjugated (USP) Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |
Physiological Effects of Drugs Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Vitamins Micronutrients Estrogens Antineoplastic Agents, Hormonal Antineoplastic Agents Anabolic Agents |